ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

ClinicalTrials.gov ID: NCT06561360

Public ClinicalTrials.gov record NCT06561360. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 7:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multi-Center, Phase II Study of Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab in Patients With Previously Untreated Hairy Cell Leukemia (HCL)

Study identification

NCT ID
NCT06561360
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
86 participants

Conditions and interventions

Interventions

  • Cladribine Drug
  • Obinutuzumab Drug
  • Rituximab Drug
  • Vemurafenib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 8, 2024
Primary completion
Sep 8, 2027
Completion
Sep 8, 2027
Last update posted
Apr 14, 2026

2024 – 2027

United States locations

U.S. sites
10
U.S. states
5
U.S. cities
10
Facility City State ZIP Site status
Dana Farber Cancer Institute Boston Massachusetts 02115 Not yet recruiting
Mayo Clinic Cancer Center Rochester Minnesota 55905 Not yet recruiting
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) Basking Ridge New Jersey 07920 Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 Recruiting
Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) Commack New York 11725 Recruiting
Memorial Sloan Kettering Westchester (All Protocol Activities) Harrison New York 10604 Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York 10065 Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York 11553 Recruiting
Ohio State University Columbus Ohio 43210 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06561360, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06561360 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →